Please try another search
For the fiscal year ended 31 December 2010, VIA Pharmaceuticals Inc revenues was not reported. Net loss decreased 54% to $9.6M. Lower net loss reflects Research & Develop. decrease of 70% to $1.8M (expense), Interest expense decrease of 54% to $3.6M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$1.05 to -$0.47.
Period Ending: | Dec 31, 2010 | Sep 30, 2010 | Jun 30, 2010 | Mar 31, 2010 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -8.24 | -1.21 | -1.39 | -2.54 |
Net Income | -8.28 | -2.12 | -2.09 | -2.92 |
Period Ending: | Dec 31, 2010 | Sep 30, 2010 | Jun 30, 2010 | Mar 31, 2010 |
---|---|---|---|---|
Total Assets | 38 | 0.49 | 0.38 | 0.69 |
Total Liabilities | 1.85 | 17.18 | 15.43 | 14 |
Total Equity | 36.15 | -16.69 | -15.06 | -13.31 |
Period Ending: | Dec 31, 2010 | Sep 30, 2010 | Jun 30, 2010 | Mar 31, 2010 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | -8.95 | -4.91 | -3.88 | -2.94 |
Cash From Investing Activities | -15 | 0 | 0 | 0 |
Cash From Financing Activities | 44.28 | 3 | 1.85 | 1.25 |
Net Change in Cash | 20.33 | -1.91 | -2.03 | -1.69 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review